Iovance Biotherapeutics (IOVA) Total Liabilities (2017 - 2025)
Historic Total Liabilities for Iovance Biotherapeutics (IOVA) over the last 14 years, with Q3 2025 value amounting to $202.7 million.
- Iovance Biotherapeutics' Total Liabilities rose 12620.2% to $202.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $202.7 million, marking a year-over-year increase of 12620.2%. This contributed to the annual value of $200.0 million for FY2024, which is 218.81% up from last year.
- According to the latest figures from Q3 2025, Iovance Biotherapeutics' Total Liabilities is $202.7 million, which was up 12620.2% from $208.9 million recorded in Q2 2025.
- Iovance Biotherapeutics' Total Liabilities' 5-year high stood at $208.9 million during Q2 2025, with a 5-year trough of -$773.5 million in Q3 2024.
- Moreover, its 3-year median value for Total Liabilities was $189.8 million (2024), whereas its average is $15.4 million.
- Its Total Liabilities has fluctuated over the past 5 years, first crashed by 53377.71% in 2024, then skyrocketed by 12718.78% in 2025.
- Iovance Biotherapeutics' Total Liabilities (Quarter) stood at $195.7 million in 2023, then grew by 2.19% to $200.0 million in 2024, then rose by 1.32% to $202.7 million in 2025.
- Its Total Liabilities stands at $202.7 million for Q3 2025, versus $208.9 million for Q2 2025 and $198.9 million for Q1 2025.